Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cellectis S.A. - American Depositary Shares (NQ:CLLS)

3.920 -0.140 (-3.45%)
Streaming Delayed Price Updated: 1:08 PM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cellectis S.A. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing
From Cellectis Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 6, 2023 ↗
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million. 
Via Benzinga
News headline image
Earnings Preview: Cellectis ↗
 
Via Benzinga
News headline image
Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024
From Cellectis Inc.
Via GlobeNewswire
News headline image
CLLS Stock Earnings: Cellectis Beats EPS, Beats Revenue for Q1 2024 ↗
CLLS stock results show that Cellectis beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Cellectis Reports Financial Results for First Quarter 2024
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024
From Cellectis Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Appoints Arthur Stril as Interim Chief Financial Officer
From Cellectis Inc.
Via GlobeNewswire
News headline image
CLLS Stock Earnings: Cellectis Misses EPS, Misses Revenue for Q4 2023 ↗
CLLS stock results show that Cellectis missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis’ Shareholders Meeting to be Held on December 22, 2023
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual Meeting
From Cellectis Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Roku Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket ↗
Gainers LumiraDx Limited (NASDAQ: LMDX) shares surged 39.7% to $0.1143 in pre-market trading after falling 17% on Wednesday. LumiraDX recently announced the receipt of the Nasdaq delisting... 
Via Benzinga
News headline image
Why STAAR Surgical Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Gainers OmniLit Acquisition Corp. (NASDAQ: OLIT) jumped 53.2% to $15.53. OmniLit announced that its merger with Syntec was approved by shareholders. 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗
Pre-market stock movers are a hot topic on Thursday and we're checking out all of the biggest ones worth watching this morning! 
Via InvestorPlace
News headline image
Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023
From Cellectis Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.